Artios Pharma Ltd
Los Angeles, California
What changed
Phase II trial registered: Study of ART0380 in Patients With Biologically Selected Solid Tumors
8mo agoTrial registeredNov 6, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 44 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Phase II
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Peer position
1,440 pre-ticker oncology companies at Phase II
Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.
Compare seatsA ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
PHASE2 registered
Sep 6, 2023Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer · TERMINATED · sponsor: Artios Pharma Ltd · Study of ART0380 in Patients With Biologically Selected Solid Tumors
ClinicalTrials.gov · NCT05798611 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources